



Isabel Pidal Ladrón de Guevara

Predoctoral researcher
Neuroinmuno-Repair Group (Lab i2-04; office i2-12)
National Hospital for Paraplegics-SESCAM
Toledo, Spain

1. ACADEMIC DEGREES

- Bachelor of Biomedicine (2020). Francisco de Vitoria University. Madrid, Spain.
- Master's degree in Neuroscience (2022). Autonomous University of Madrid. Madrid, Spain.

2. RESEARCH AND PROFESSIONAL EXPERIENCE

- **2020**. Undergraduate student. Department of Pathology. Albert Einstein College of Medicine. New York, USA.
- **2020-2022**. Master student (Research Grant during Master's studies-UAM). Department of Anatomy, Histology and Neuroscience, Faculty of Medicine, Autonomous University of Madrid. Madrid, Spain.
- **2022-2023**. Research Assistant. Supported by Recovery, Transformation and Resilience Plan, funded by the European Union - Next Generation EU. Department of Molecular and Cellular Biology, National Center of Biotechnology, CSIC. Madrid, Spain.
- **2024-**. PhD student supported by a competitive research fellowship (FPU) from the Spanish Ministry of Education and Science. Neuroinmuno-Repair group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

3. PUBLICATIONS

2023

Gonzalo-Gobernado, R.; Moreno-Martínez, L.; González, P.; Dopazo, X.M.; Calvo, A.C.; ***Pidal-Ladrón de Guevara, I.***; Seisdedos, E.; Díaz-Muñoz, R.; Mellström, B.; Osta, R.; et al. Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice. *Int. J. Mol. Sci.* 2023, 24, 15783.

<https://doi.org/10.3390/ijms242115783>

4. SCIENTIFIC COMMUNICATIONS IN NATIONAL/INTERNATIONAL CONFERENCES

2023

Gonzalo-Gobernado, R.; Moreno-Martínez, L.; González, P.; Dopazo, X.M.; Calvo, A.C.; ***Pidal-Ladrón de Guevara, I.***; Seisdedos, E.; Díaz-Muñoz, R.; Mellström, B.; Osta, R.; et al. **Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice.** International Congress on Neurodegenerative Diseases (CIBERNED) 2023. Málaga, Spain. Poster.

5. GRANTED RESEARCH PROJECTS

- Projects supported by private entities:

2022-2024: Mechanistic analysis of the ATF6/DREAM interaction in ALS and preparation of target validation using genetic analysis. Asahi Kasei Pharma. **Total amount: 100.000 €.**
Role: Associated Research. **PI:** José R. Naranjo.